Oncogenic role of the Notch pathway in primary liver cancer (Review) Corrigendum in /10.3892/ol.2016.5145

Lu,Jie; Xia,Yujing; Chen,Kan; Zheng,Yuanyuan; Wang,Jianrong; Lu,Wenxia; Yin,Qin; Wang,Fan; Zhou,Yingqun; Guo,Chuanyong

doi:10.3892/ol.2016.4609

Oncogenic role of the Notch pathway in primary liver cancer (Review)

Corrigendum in: /10.3892/ol.2016.5145

Authors:
- Jie Lu
- Yujing Xia
- Kan Chen
- Yuanyuan Zheng
- Jianrong Wang
- Wenxia Lu
- Qin Yin
- Fan Wang
- Yingqun Zhou
- Chuanyong Guo
View Affiliations

Affiliations: Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University, School of Medicine, Shanghai 200072, P.R. China
Published online on: May 18, 2016 https://doi.org/10.3892/ol.2016.4609
Pages: 3-10

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Primary liver cancer, which includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, is one of the most common malignancies and the third leading cause of cancer‑associated mortality, worldwide. Despite the development of novel therapies, the prognosis of liver cancer patients remains extremely poor. Thus, investigation of the genetic background and molecular mechanisms underlying the development and progression of this disease has gained significant attention. The Notch signaling pathway is a crucial determinant of cell fate during development and disease in several organs. In the liver, Notch signaling is involved in biliary tree development and tubulogenesis, and is also significant in the development of HCC and ICC. These findings suggest that the modulation of Notch pathway activity may have therapeutic relevance. The present review summarizes Notch signaling during HCC and ICC development and discusses the findings of recent studies regarding Notch expression, which reveal novel insights into its function in liver cancer progression.

View Figures

View References

1	Tinkle CL and Haas-Kogan D: Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics. 6:207–219. 2012.PubMed/NCBI
2	Jie L, Fan W, Weiqi D, Yingqun Z, Ling X, Miao S, Ping C and Chuanyong G: The hippo-yes association protein pathway in liver cancer. Gastroenterol Res Pract. 2013:1870702013. View Article : Google Scholar : PubMed/NCBI
3	Hackl C, Schlitt HJ, Kirchner GI, Knoppke B and Loss M: Liver transplantation for malignancy: Current treatment strategies and future perspectives. World J Gastroenterol. 20:5331–5344. 2014. View Article : Google Scholar : PubMed/NCBI
4	Lam PH, Obirieze AC, Ortega G, Nwokeabia I, Onyewu S, Purnell SD, Samimi MM, Weeks CB, Lee EL, Shokrani B, et al: Characterization of hepatitis B and C among liver transplant recipients with hepatocellular carcinoma: An analysis of the Nationwide Inpatient Sample Database. Transplant Proc. 48:123–127. 2016. View Article : Google Scholar : PubMed/NCBI
5	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
6	Wang F, He L, Dai WQ, Xu YP, Wu D, Lin CL, Wu SM, Cheng P, Zhang Y, Shen M, et al: Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. PLoS One. 7:e506382012. View Article : Google Scholar : PubMed/NCBI
7	Dai W, Wang F, He L, Lin C, Wu S, Chen P, Zhang Y, Shen M, Wu D, Wang C, et al: Genistein inhibits hepatocellular carcinoma cell migration by reversing the epithelial-mesenchymal transition: Partial mediation by the transcription factor NFAT1. Mol Carcinog. 54:301–311. 2015. View Article : Google Scholar : PubMed/NCBI
8	Roca C and Adams RH: Regulation of vascular morphogenesis by notch signaling. Genes Dev. 21:2511–2524. 2007. View Article : Google Scholar : PubMed/NCBI
9	Dou GR, Wang YC, Hu XB, Hou LH, Wang CM, Xu JF, Wang YS, Liang YM, Yao LB, Yang AG and Han H: RBP-J, the transcription factor downstream of Notch receptors, is essential for the maintenance of vascular homeostasis in adult mice. FASEB J. 22:1606–1617. 2008. View Article : Google Scholar : PubMed/NCBI
10	Fortini ME: Notch signaling: The core pathway and its posttranslational regulation. Dev Cell. 16:633–647. 2009. View Article : Google Scholar : PubMed/NCBI
11	Coffinier C, Gresh L, Fiette L, Tronche F, Schütz G, Babinet C, Pontoglio M, Yaniv M and Barra J: Bile system morphogenesis defects and liver dysfunction upon targeted deletion of HNF1beta. Development. 129:1829–1838. 2002.PubMed/NCBI
12	Zong Y, Panikkar A, Xu J, Antoniou A, Raynaud P, Lemaigre F and Stanger BZ: Notch signaling controls liver development by regulating biliary differentiation. Development. 136:1727–1739. 2009. View Article : Google Scholar : PubMed/NCBI
13	Morell CM, Fiorotto R, Fabris L and Strazzabosco M: Notch signalling beyond liver development: emerging concepts in liver repair and oncogenesis. Clin Res Hepatol Gastroenterol. 37:447–454. 2013. View Article : Google Scholar : PubMed/NCBI
14	Ahn KJ, Yoon JK, Kim GB, Kwon BS, Go JM, Moon JS, Bae EJ and Noh CI: Alagille syndrome and a JAG1 mutation: 41 Cases of experience at a single center. Korean J Pediatr. 58:392–397. 2015. View Article : Google Scholar : PubMed/NCBI
15	Liu X, Zuo Y, Sun W, Zhang W, Lv H, Huang Y, Xiao J, Yuan Y and Wang Z: The genetic spectrum and the evaluation of CADASIL screening scale in Chinese patients with NOTCH3 mutations. J Neurol Sci. 354:63–69. 2015. View Article : Google Scholar : PubMed/NCBI
16	Oda T, Elkahloun AG, Pike BL, Okajima K, Krantz ID, Genin A, Piccoli DA, Meltzer PS, Spinner NB, Collins FS and Chandrasekharappa SC: Mutations in the human Jagged1 gene are responsible for alagille syndrome. Nat Genet. 16:235–242. 1997. View Article : Google Scholar : PubMed/NCBI
17	Brooks AS and Dooijes D: From gene to disease: Arteriohepatic dysplasia or Alagille syndrome. Ned Tijdschr Geneeskd. 147:1213–1215. 2003.PubMed/NCBI
18	McDaniell R, Warthen DM, Sanchez-Lara PA, Pai A, Krantz ID, Piccoli DA and Spinner NB: NOTCH2 mutations cause alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am J Hum Genet. 79:169–173. 2006. View Article : Google Scholar : PubMed/NCBI
19	Habib R, Dommergues JP, Gubler MC, Hadchouel M, Gautier M, Odievre M and Alagille D: Glomerular mesangiolipidosis in alagille syndrome (arteriohepatic dysplasia). Pediatr Nephrol. 1:455–464. 1987. View Article : Google Scholar : PubMed/NCBI
20	Nyfeler Y, Kirch RD, Mantei N, Leone DP, Radtke F, Suter U and Taylor V: Jagged1 signals in the postnatal subventricular zone are required for neural stem cell self-renewal. EMBO J. 24:3504–3515. 2005. View Article : Google Scholar : PubMed/NCBI
21	Gridley T: Notch signaling in the vasculature. Curr Top Dev Biol. 92:277–309. 2010. View Article : Google Scholar : PubMed/NCBI
22	Cheng P, Dai W, Wang F, Lu J, Shen M, Chen K, Li J, Zhang Y, Wang C, Yang J, et al: Ethyl pyruvate inhibits proliferation and induces apoptosis of hepatocellular carcinoma via regulation of the HMGB1-RAGE and AKT pathways. Biochem Biophys Res Commun. 443:1162–1168. 2014. View Article : Google Scholar : PubMed/NCBI
23	Croquelois A, Blindenbacher A, Terracciano L, Wang X, Langer I, Radtke F and Heim MH: Inducible inactivation of Notch1 causes nodular regenerative hyperplasia in mice. Hepatology. 41:487–496. 2005. View Article : Google Scholar : PubMed/NCBI
24	Dill MT, Rothweiler S, Djonov V, Hlushchuk R, Tornillo L, Terracciano L, Meili-Butz S, Radtke F, Heim MH and Semela D: Disruption of Notch1 induces vascular remodeling, intussusceptive angiogenesis and angiosarcomas in livers of mice. Gastroenterolog. 142:967–977. 2012. View Article : Google Scholar
25	Geisler F, Nagl F, Mazur PK, Lee M, Zimber-Strobl U, Strobl LJ, Radtke F, Schmid RM and Siveke JT: Liver-specific inactivation of Notch2, but not Notch1, compromises intrahepatic bile duct development in mice. Hepatology. 48:607–616. 2008. View Article : Google Scholar : PubMed/NCBI
26	Chen JY, Feng L, Zhang HL, Li JC, Yang XW, Cao XL, Liu L, Qin HY, Liang YM and Han H: Differential regulation of bone marrow-derived endothelial progenitor cells and endothelial outgrowth cells by the notch signaling pathway. PLoS One. 7:e436432012. View Article : Google Scholar : PubMed/NCBI
27	Krebs LT, Xue Y, Norton CR, Shutter JR, Maguire M, Sundberg JP, Gallahan D, Closson V, Kitajewski J, Callahan R, et al: Notch signaling is essential for vascular morphogenesis in mice. Genes Dev. 14:1343–1352. 2000.PubMed/NCBI
28	Hofmann JJ, Zovein AC, Koh H, Radtke F, Weinmaster G and Iruela-Arispe ML: Jagged1 in the portal vein mesenchyme regulates intrahepatic bile duct development: Insights into alagille syndrome. Development. 137:4061–4072. 2010. View Article : Google Scholar : PubMed/NCBI
29	Jiang R, Lan Y, Chapman HD, Shawber C, Norton CR, Serreze DV, Weinmaster G and Gridley T: Defects in limb, craniofacial and thymic development in Jagged2 mutant mice. Genes Dev. 12:1046–1057. 1998. View Article : Google Scholar : PubMed/NCBI
30	Redeker C, Schuster-Gossler K, Kremmer E and Gossler A: Normal development in mice over-expressing the intracellular domain of DLL1 argues against reverse signaling by DLL1 in vivo. PLoS One. 8:e790502013. View Article : Google Scholar : PubMed/NCBI
31	Djokovic D, Trindade A, Gigante J, Badenes M, Silva L, Liu R, Li X, Gong M, Krasnoperov V, Gill PS and Duarte A: Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis. BMC Cancer. 10:6412010. View Article : Google Scholar : PubMed/NCBI
32	Turnpenny PD, Whittock N, Duncan J, Dunwoodie S, Kusumi K and Ellard S: Novel mutations in DLL3, a somitogenesis gene encoding a ligand for the Notch signalling pathway, cause a consistent pattern of abnormal vertebral segmentation in spondylocostal dysostosis. J Med Genet. 40:333–339. 2003. View Article : Google Scholar : PubMed/NCBI
33	Gale NW, Dominguez MG, Noguera I, Pan L, Hughes V, Valenzuela DM, Murphy AJ, Adams NC, Lin HC, Holash J, Thurston G and Yancopoulos GD: Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci USA. 101:15949–15954. 2004. View Article : Google Scholar : PubMed/NCBI
34	Traustadóttir GÁ, Jensen CH, Thomassen M, Beck HC, Mortensen SB, Laborda J, Baladrón V, Sheikh SP and Andersen DC: Evidence of non-canonical NOTCH signaling: Delta-like 1 homolog (DLK1) directly interacts with the NOTCH1 receptor in mammals. Cell Signal. 28:246–254. 2016. View Article : Google Scholar : PubMed/NCBI
35	Hayashi T, Gust KM, Wyatt AW, Goriki A, Jäger W, Awrey S, Li N, Oo HZ, Altamirano-Dimas M, Buttyan R, et al: Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy. Clin Cancer Res. Jan 14–2016.(Epub ahead of print). View Article : Google Scholar
36	Conlon RA, Reaume AG and Rossant J: Notch1 is required for the coordinate segmentation of somites. Development. 121:1533–1545. 1995.PubMed/NCBI
37	Swiatek PJ, Lindsell CE, del Amo FF, Weinmaster G and Gridley T: Notch1 is essential for postimplantation development in mice. Genes Dev. 8:707–719. 1994. View Article : Google Scholar : PubMed/NCBI
38	Kamath BM, Bauer RC, Loomes KM, Chao G, Gerfen J, Hutchinson A, Hardikar W, Hirschfield G, Jara P, Krantz ID, et al: NOTCH2 mutations in Alagille syndrome. J Med Genet. 49:138–144. 2012. View Article : Google Scholar : PubMed/NCBI
39	Jeliazkova P1, Jörs S, Lee M, Zimber-Strobl U, Ferrer J, Schmid RM, Siveke JT and Geisler F: Canonical Notch2 signaling determines biliary cell fates of embryonic hepatoblasts and adult hepatocytes independent of Hes1. Hepatology. 57:2469–2479. 2013. View Article : Google Scholar : PubMed/NCBI
40	Falix FA, Aronson DC, Lamers WH and Gaemers IC: Possible roles of DLK1 in the notch pathway during development and disease. Biochim Biophys Acta. 1822:988–995. 2012. View Article : Google Scholar : PubMed/NCBI
41	Pippucci T, Maresca A, Magini P, Cenacchi G, Donadio V, Palombo F, Papa V, Incensi A, Gasparre G, Valentino ML, et al: Homozygous NOTCH3 null mutation and impaired NOTCH3 signaling in recessive early-onset arteriopathy and cavitating leukoencephalopathy. EMBO Mol Med. 7:848–858. 2015. View Article : Google Scholar : PubMed/NCBI
42	Chen YX, Weng ZH and Zhang SL: Notch3 regulates the activation of hepatic stellate cells. World J Gastroenterol. 18:1397–1403. 2012. View Article : Google Scholar : PubMed/NCBI
43	Carlson TR, Yan Y, Wu X, Lam MT, Tang GL, Beverly LJ, Messina LM, Capobianco AJ, Werb Z and Wang R: Endothelial expression of constitutively active Notch4 elicits reversible arteriovenous malformations in adult mice. Proc Natl Acad Sci USA. 102:9884–9889. 2005. View Article : Google Scholar : PubMed/NCBI
44	Rocha SF, Lopes SS, Gossler A and Henrique D: Dll1 and Dll4 function sequentially in the retina and pV2 domain of the spinal cord to regulate neurogenesis and create cell diversity. Dev Biol. 328:54–65. 2009. View Article : Google Scholar : PubMed/NCBI
45	de Hrabĕ Angelis M, McIntyre J II and Gossler A: Maintenance of somite borders in mice requires the delta homologue DII1. Nature. 386:717–721. 1997. View Article : Google Scholar : PubMed/NCBI
46	Maemura K, Yoshikawa H, Yokoyama K, Ueno T, Kurose H, Uchiyama K and Otsuki Y: Delta-like 3 is silenced by methylation and induces apoptosis in human hepatocellular carcinoma. Int J Oncol. 42:817–822. 2013.PubMed/NCBI
47	Castel D, Mourikis P, Bartels SJ, Brinkman AB, Tajbakhsh S and Stunnenberg HG: Dynamic binding of RBPJ is determined by notch signaling status. Genes Dev. 27:1059–1071. 2013. View Article : Google Scholar : PubMed/NCBI
48	Yuan Z, Friedmann DR, VanderWielen BD, Collins KJ and Kovall RA: Characterization of CSL (CBF-1, Su (H), Lag-1) mutants reveals differences in signaling mediated by Notch1 and Notch2. J Biol Chem. 287:34904–34916. 2012. View Article : Google Scholar : PubMed/NCBI
49	Kopan R and Ilagan MX: The canonical notch signaling pathway: Unfolding the activation mechanism. Cell. 137:216–233. 2009. View Article : Google Scholar : PubMed/NCBI
50	Borggrefe T and Oswald F: The notch signaling pathway: Transcriptional regulation at notch target genes. Cell Mol Life Sci. 66:1631–1646. 2009. View Article : Google Scholar : PubMed/NCBI
51	Kovall RA and Blacklow SC: Mechanistic insights into notch receptor signaling from structural and biochemical studies. Curr Top Dev Biol. 92:31–71. 2010. View Article : Google Scholar : PubMed/NCBI
52	Clayton T, Poe MM, Rallapalli S, Biawat P, Savić MM, Rowlett JK, Gallos G, Emala CW, Kaczorowski CC, Stafford DC, Arnold LA and Cook JM: A Review of the Updated Pharmacophore for the Alpha 5 GABA(A) Benzodiazepine Receptor Model. Int J Med Chem. 2015:4302482015.PubMed/NCBI
53	Zou JH, Xue TC, Sun C, Li Y, Liu BB, Sun RX, Chen J, Ren ZG and Ye SL: Prognostic significance of Hes-1, a downstream target of notch signaling in hepatocellular carcinoma Asian Pac. J Cancer Prev. 16:3811–3816. 2015.
54	Friedmann DR and Kovall RA: Thermodynamic and structural insights into CSL-DNA complexes. Protein Sci. 19:34–46. 2010.PubMed/NCBI
55	Dai W, Wang C, Wang F, Wang Y, Shen M, Chen K, Cheng P, Zhang Y, Yang J, Zhu R, et al: Anti-miR-197 inhibits migration in HCC cells by targeting KAI 1/CD82. Biochem Biophys Res Commun. 446:541–548. 2014. View Article : Google Scholar : PubMed/NCBI
56	Wang H, Zou J, Zhao B, Johannsen E, Ashworth T, Wong H, Pear WS, Schug J, Blacklow SC, Arnett KL, et al: Genome-wide analysis reveals conserved and divergent features of Notch1/RBPJ binding in human and murine T-lymphoblastic leukemia cells. Proc Natl Acad Sci USA. 108:14908–14913. 2011. View Article : Google Scholar : PubMed/NCBI
57	Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I, et al: Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature. 444:1083–1087. 2006. View Article : Google Scholar : PubMed/NCBI
58	Sumazaki R, Shiojiri N, Isoyama S, Masu M, Keino-Masu K, Osawa M, Nakauchi H, Kageyama R and Matsui A: Conversion of biliary system to pancreatic tissue in Hes1-deficient mice. Nat Genet. 36:83–87. 2004. View Article : Google Scholar : PubMed/NCBI
59	Wolfe MS, Esler WP and Das C: Continuing strategies for inhibiting alzheimer's gamma-secretase. J Mol Neurosci. 19:83–87. 2002. View Article : Google Scholar : PubMed/NCBI
60	Tchorz JS, Kinter J, Müller M, Tornillo L, Heim MH and Bettler B: Notch2 signaling promotes biliary epithelial cell fate specification and tubulogenesis during bile duct development in mice. Hepatology. 50:871–879. 2009. View Article : Google Scholar : PubMed/NCBI
61	Zhang QD, Xu MY, Cai XB, Qu Y, Li ZH and Lu LG: Myofibroblastic transformation of rat hepatic stellate cells: The role of Notch signaling and epithelial-mesenchymal transition regulation. Eur Rev Med Pharmacol Sci. 19:4130–4138. 2015.PubMed/NCBI
62	Wen L, Liang C, Chen E, Chen W, Liang F, Zhi X, Wei T, Xue F, Li G, Yang Q, Gong W, Feng X, Bai X and Liang T: Regulation of Multi-drug Resistance in hepatocellular carcinoma cells is TRPC6/Calcium Dependent. Sci Rep. 6:232692016. View Article : Google Scholar : PubMed/NCBI
63	Chen QY, Jiao DM, Wang J, Hu H, Tang X, Chen J, Mou H and Lu W: miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET. Oncotarget. Mar 21–2016.(Epub ahead of print). doi: 10.18632/oncotarget.8229. View Article : Google Scholar
64	Lombardo Y, Faronato M, Filipovic A, Vircillo V, Magnani L and Coombes RC: Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells. Breast Cancer Res. 16:R622014. View Article : Google Scholar : PubMed/NCBI
65	Espinoza I, Pochampally R, Xing F, Watabe K and Miele L: Notch signaling: Targeting cancer stem cells and epithelial-to-mesenchymal transition. Onco Targets Ther. 6:1249–1259. 2013.PubMed/NCBI
66	Kang H, An HJ, Song JY, Kim TH, Heo JH, Ahn DH and Kim G: Notch3 and Jagged2 contribute to gastric cancer development and to glandular differentiation associated with MUC2 and MUC5AC expression. Histopathology. 61:576–586. 2012.PubMed/NCBI
67	Kodama Y, Hijikata M, Kageyama R, Shimotohno K and Chiba T: The role of notch signaling in the development of intrahepatic bile ducts. Gastroenterology. 127:1775–1786. 2004. View Article : Google Scholar : PubMed/NCBI
68	Cheng HT, Kim M, Valerius MT, Surendran K, Schuster-Gossler K, Gossler A, McMahon AP and Kopan R: Notch2, but not Notch1, is required for proximal fate acquisition in the mammalian nephron. Development. 134:801–811. 2007. View Article : Google Scholar : PubMed/NCBI
69	Loomes KM, Taichman DB, Glover CL, Williams PT, Markowitz JE, Piccoli DA, Baldwin HS and Oakey RJ: Characterization of notch receptor expression in the developing mammalian heart and liver. Am J Med Genet. 112:181–189. 2002. View Article : Google Scholar : PubMed/NCBI
70	Pei J, Tang Z, Zang G and Yu Y: Blockage of Notch1 signaling modulates the T-helper (Th)1/Th2 cell balance in chronic hepatitis B patients. Hepatol Res. 40:799–805. 2010. View Article : Google Scholar : PubMed/NCBI
71	Nijjar SS, Crosby HA, Wallace L, Hubscher SG and Strain AJ: Notch receptor expression in adult human liver: A possible role in bile duct formation and hepatic neovascularization. Hepatology. 34:1184–1192. 2001. View Article : Google Scholar : PubMed/NCBI
72	Alvaro D, Bragazzi MC, Benedetti A, Fabris L, Fava G, Invernizzi P, Marzioni M, Nuzzo G, Strazzabosco M and Stroffolini T: Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the ‘Cholangiocarcinoma’ committee of the Italian association for the study of liver disease. Dig Liver Dis. 43:60–65. 2011. View Article : Google Scholar : PubMed/NCBI
73	Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun Z, et al: A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 12:410–416. 2006. View Article : Google Scholar : PubMed/NCBI
74	Gao J, Chen Y, Wu KC, Liu J, Zhao YQ, Pan YL, Du R, Zheng GR, Xiong YM, Xu HL and Fan DM: RUNX3 directly interacts with intracellular domain of Notch1 and suppresses notch signaling in hepatocellular carcinoma cells. Exp Cell Res. 316:149–157. 2010. View Article : Google Scholar : PubMed/NCBI
75	Sekiya S and Suzuki A: Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J Clin Invest. 122:3914–3918. 2012. View Article : Google Scholar : PubMed/NCBI
76	Weng AP and Aster JC: Multiple niches for notch in cancer: Context is everything. Curr Opin Genet De. 14:48–54. 2004. View Article : Google Scholar
77	Lu J, Zhou Y, Hu T, Zhang H, Shen M, Cheng P, Dai W, Wang F, Chen K, Zhang Y, et al: Notch Signaling Coordinates Progenitor Cell-Mediated Biliary Regeneration Following Partial Hepatectomy. Sci Rep. 6:227542016. View Article : Google Scholar : PubMed/NCBI
78	Espinoza I and Miele L: Notch inhibitors for cancer treatment. Pharmacol Ther. 139:95–110. 2013. View Article : Google Scholar : PubMed/NCBI
79	Hayashi Y, Osanai M and Lee GH: NOTCH2 signaling confers immature morphology and aggressiveness in human hepatocellular carcinoma cells. Oncol Rep. 34:1650–1658. 2015.PubMed/NCBI
80	Kohn A, Rutkowski TP, Liu Z, Mirando AJ, Zuscik MJ, O'Keefe RJ and Hilton MJ: Notch signaling controls chondrocyte hypertrophy via indirect regulation of Sox9. Bone Res. 3:150212015. View Article : Google Scholar : PubMed/NCBI
81	Fowlkes BJ and Robey EA: A reassessment of the effect of activated Notch1 on CD4 and CD8 T cell development. J Immunol. 169:1817–1821. 2002. View Article : Google Scholar : PubMed/NCBI
82	Zhu R, Yang J, Xu L, Dai W, Wang F, Shen M, Zhang Y, Zhang H, Chen K, Cheng P, et al: Diagnostic performance of des-γ-carboxy prothrombin for hepatocellular carcinoma: A meta-analysis. Gastroenterol Res Pract. 2014:5293142014. View Article : Google Scholar : PubMed/NCBI
83	Nalesnik MA, Tseng G, Ding Y, Xiang GS, Zheng ZL, Yu Y, Marsh JW, Michalopoulos GK and Luo JH: Gene deletions and amplifications in human hepatocellular carcinomas: Correlation with hepatocyte growth regulation. Am J Pathol. 180:1495–1508. 2012. View Article : Google Scholar : PubMed/NCBI
84	Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y, Toffanin S, Rodriguez-Carunchio L, Solé M, Thung S, Stanger BZ and Llovet JM: Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology. 143:1660–1669. 2012. View Article : Google Scholar : PubMed/NCBI
85	Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, Gores GJ, Dombrowski F, Evert M, Chen X and Willenbring H: Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 122:2911–2915. View Article : Google Scholar : PubMed/NCBI
86	Viatour P, Ehmer U, Saddic LA, Dorrell C, Andersen JB, Lin C, Zmoos AF, Mazur PK, Schaffer BE, Ostermeier A, et al: Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med. 208:1963–1976. 2011. View Article : Google Scholar : PubMed/NCBI
87	Vincent F, Bonnin P, Clemessy M, Contrerès JO, Lamandé N, Gasc JM, Vilar J, Hainaud P, Tobelem G, Corvol P and Dupuy E: Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice. Cancer Res. 69:2853–2860. 2009. View Article : Google Scholar : PubMed/NCBI
88	Wang F, Dai W, Wang Y, Shen M, Chen K, Cheng P, Zhang Y, Wang C, Li J, Zheng Y, et al: The synergistic in vitro and in vivo antitumor effect of combination therapy with salinomycin and 5-fluorouracil against hepatocellular carcinoma. PLoS One. 9:e974142014. View Article : Google Scholar : PubMed/NCBI
89	Sekiya S and Suzuki A: Intrahepatic cholangiocarcinoma can arise from notch-mediated conversion of hepatocytes. J Clin Invest. 122:3914–3918. 2012. View Article : Google Scholar : PubMed/NCBI
90	Ishimura N, Bronk SF and Gores GJ: Inducible nitric oxide synthase up-regulates notch-1 in mouse cholangiocytes: Implications for carcinogenesis. Gastroenterology. 128:1354–1368. 2005. View Article : Google Scholar : PubMed/NCBI
91	Roma J, Masià A, Reventós J, de Sánchez Toledo J and Gallego S: Notch Pathway Inhibition Significantly Reduces Rhabdomyosarcoma Invasiveness and Mobility. Vitro Clin Cancer Res. 17:505–513. 2011. View Article : Google Scholar : PubMed/NCBI
92	Olsauskas-Kuprys R, Zlobin A and Osipo C: Gamma secretase inhibitors of notch signaling. Onco Targets Ther. 6:943–955. 2013.PubMed/NCBI